Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ZIVO Bioscience, Inc. (ZIVO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, annual and quarterly reports and other documents filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with a Commission File Number of 000-30415, ZIVO uses these filings to report material events, describe its business and update investors on governance and financial matters.
For a research and development company like ZIVO, SEC filings are a key source of information on its biotech and agtech activities involving proprietary algal and bacterial strains, biologically active molecules and complexes, and related intellectual property. Filings can explain how the company characterizes its focus on human and animal health applications, outline risk factors and summarize relationships with collaborators and counterparties.
Current reports on Form 8-K, such as the filing describing the resignation of a Chief Financial Officer and the appointment of an Interim Chief Financial Officer under an independent contractor services agreement, document significant management changes and associated compensation arrangements. Investors can also use this page to monitor future 10-K annual reports and 10-Q quarterly reports for updates on ZIVO’s R&D programs, liquidity, and any disclosed licensing or collaboration agreements.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in plain language, helping readers quickly understand lengthy documents. Real-time updates from EDGAR ensure that new ZIVO filings appear promptly, while access to ownership and insider transaction reports, such as Form 4 when filed, allows users to track equity-related activity by directors and officers. This combination of raw filings and AI analysis offers a structured way to review ZIVO’s regulatory history and ongoing disclosure record.
Zivo Bioscience, Inc. (ZIVO) director Alison Cornell received a grant of 1,223 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $12,476.71. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035
This transaction increases the reporting person’s direct beneficial ownership by 1,223 underlying shares. The filing is a routine director compensation disclosure showing equity issued instead of cash fees to align compensation with shareholder interests.
Laith Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), reported a purchase of 15,322 shares of the company's common stock on 09/30/2025 at a price of $15.99 per share. After the transaction, the filing shows beneficial ownership of 573,436 shares held indirectly through HEP Investments LLC. The Form 4 was signed on 10/02/2025.
This report documents an insider acquisition, increasing the reporting person's indirect stake via an investment vehicle. The filing does not disclose any derivative transactions or additional context for the purchase beyond the amounts, price, and ownership form.